SCHEMBL3655628

SCHEMBL3655628

[Pd]P(c1ccccc1)c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 4/20 0.53
CYP3A4 P08684 1/20 0.53
ESR1 P03372 4/20 0.39
ESR2 Q92731 4/20 0.39
ALDH1A1 P00352 5/20 0.39
KDM4E B2RXH2 1/20 0.35
GAA P10253 1/20 0.35
MAPT P10636 2/20 0.32
MAPK1 P28482 1/20 0.32
TSHR P16473 4/20 0.32
CA1 P00915 2/20 0.32
CA2 P00918 2/20 0.32
CA9 Q16790 2/20 0.32
CA12 O43570 1/20 0.32
GLA P06280 1/20 0.32
CA3 P07451 1/20 0.32
CA4 P22748 1/20 0.32
CA14 Q9ULX7 1/20 0.32
LMNA P02545 1/20 0.32
ALOX12 P18054 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ethane SCHEMBL8672611 0.94 TDP1 (0.47) TDP1CYP3A4ESR1ESR2ALDH1A1
Propane SCHEMBL8522373 0.88 TDP1 (0.43) TDP1CYP3A4ESR1ESR2ALDH1A1
SCHEMBL18241084 0.84 TDP1 (0.39) TDP1CYP3A4ESR1ESR2ALDH1A1
SCHEMBL17414853 0.80 TDP1 (0.36) TDP1CYP3A4ESR1ESR2
SCHEMBL2733013 0.80 CYP3A4 (0.36) TDP1CYP3A4ESR1ESR2LMNA
Hydrochloric Acid SCHEMBL19723221 0.78 CYP3A4 (0.35) TDP1CYP3A4ESR1ESR2
SCHEMBL987669 0.74 TDP1 (0.92) TDP1CYP3A4ESR1ESR2ALDH1A1
SCHEMBL2387556 0.71 TDP1 (0.86) TDP1CYP3A4ESR1ESR2ALDH1A1
Benzene SCHEMBL6890099 0.69 TDP1 (1.00) TDP1CYP3A4ESR1ESR2ALDH1A1
SCHEMBL101 0.69 TDP1 (1.00) TDP1CYP3A4ESR1ESR2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114907381-B Photosensitizer with thiadiazolo [3,4-g ] quinoxaline structure with distorted molecular framework, preparation and application thereof 中国科学院理化技术研究所 2023-09-29 CN claimed
CN-110028392-B Method for isomerizing and synthesizing isopropenal by using methylbutynol 山东新和成药业有限公司 2021-04-13 CN claimed
CN-110028392-A A kind of method of methyl butynol iso-synthesis isoamyl olefine aldehydr 山东新和成药业有限公司 2019-07-19 CN claimed
CN-107008501-A A kind of hydrophilic mesoporous silicon nanosphere of the bimetallic support type containing palladium and chiral ruthenium complex and preparation method thereof 上海师范大学 2017-08-04 CN claimed
CN-103962152-B A kind of Ru-Pd bimetallic load type chiral catalyst and preparation technology thereof 上海师范大学 2016-07-06 CN claimed
CN-104941686-A Egg shell-like structure palladium ruthenium bimetallic functionalization mesoporous nanometer catalyst and preparation method thereof UNIV SHANGHAI 2015-09-30 CN claimed
CN-103962152-A Ru-Pd bi-metal loading chiral catalyst and preparation technology thereof UNIV SHANGHAI 2014-08-06 CN claimed
EP-3833668-B1 PRMT5 INHIBITORS MERCK SHARP & DOHME LLC (US) 2025-03-19 EP disclosed
EP-4436956-A1 LIGANDS SPECIFICALLY TARGETING VESICULAR GLUTAMATE TRANSPORTERS FOR SUPER-RESOLUTION IMAGING Sorbonne Université (FR) 2024-10-02 EP disclosed
CN-113348165-B 1,2, 4-Triazin-3 (2H) -one compounds for the treatment of hyperproliferative diseases 拜耳股份有限公司 2024-06-25 CN disclosed
US-11993602-B2 PRMT5 inhibitors MERCK SHARP & DOHME LLC (US) 2024-05-28 US disclosed
CN-117295744-A Method for producing benzoxazole derivative having bicyclic piperazine ring or salt thereof, and method for producing raw material therefor 明治制果药业株式会社 2023-12-26 CN disclosed
CN-116854630-A Methods and intermediates for preparing therapeutic compounds useful in the treatment of retroviral infections 吉利德科学公司 2023-10-10 CN disclosed
EP-2203499-A1 PROCESS FOR PREPARATION OF CONDUCTING POLYMERS BASF SE (DE) 2010-07-07 EP disclosed
WO-2009053468-A1 PROCESS FOR PREPARATION OF CONDUCTING POLYMERS BASF SE (DE) 2009-04-30 WO disclosed
CN-1953982-A 4-substituted 1,5-dihydro-pyrido(3,2-b)indol-2-ones TIBOTEC PHARM LTD (IE) 2007-04-25 CN disclosed
WO-2005066243-A1 WATER-SOLUBLE POLYTHIOPHENE POLYMERS RIEKE METALS, INC. (US) 2005-07-21 WO disclosed
US-5964919-A STABILIZING THE ACTIVE ZINC BY SUSPENDING IN A CONTAINER WITH AN SOLVENT SELECT FROM ETHER, HYDROCARBON, AROMATIC HYDROCARABON OR APROTIC SOLVENT UNDER INERT GAS, SEALING THE CONTAINER BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) 1999-10-12 US disclosed
WO-1993015086-A1 HIGHLY REACTIVE FORMS OF ZINC AND REAGENTS THEREOF BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) 1993-08-05 WO disclosed
WO-1993003071-A1 PREPARATION OF FUNCTIONALIZED POLYMERS UTILIZING A REACTIVE FORM OF CALCIUM BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) 1993-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11993602-B2 PRMT5 inhibitors PRMT5, PRMT1, PRMT6 TDP1 1201/4885CYP3A4 2057/4885ESR1 3863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.